BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Pembrolizumab: trial readouts and FDA decisions
21 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 32 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Merck Sharp & Dohme LLC, AstraZeneca, GlaxoSmithKline, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Seagen, a wholly owned subsidiary of Pfizer, OncoC4, Inc., Pfizer, Hoffmann-La Roche. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-20 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer | Endometrial Neoplasms | active not recruiting | 990 |
| 2026-12 est. | P2 | Eikon Therapeutics EIKN | NCT06246110 A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | NSCLC | active not recruiting | 70 |
| 2026-12 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients Wi | Non-Small Cell Lung Cancer | active not recruiting | 432 |
| 2026-12-10 est. | P3 | Boehringer Ingelheim | NCT06151574 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standar | Lung Cancer, Non-squamous, Non-small Cell | active not recruiting | 428 |
| 2026-12-11 est. | P2 | Seagen, a wholly owned subsidiary of Pfizer | NCT04879329 A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Urothelial Carcinoma | recruiting | 372 |
| 2026-12-14 est. | P3 | Amgen AMGN | NCT06430866 Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | active not recruiting | 163 |
| 2026-12-15 est. | P1/P2 | PMV Pharmaceuticals, Inc PMVP | NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung C | recruiting | 300 |
| 2026-12-15 est. | P1/P2 | GV20 Therapeutics | NCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | Solid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC); Squamous Head and Neck Carcinoma; | recruiting | 365 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06797297 A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal | Melanoma | active not recruiting | 203 |
| 2027-01 est. | P1/P2 | BicycleTx Limited | NCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Urinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Hormone Receptor Positive, HER2-negative | active not recruiting | 329 |
| 2027-01 est. | P3 | Akeso | NCT06601335 A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Head and Neck Squamous Cell Carcinoma | recruiting | 510 |
| 2027-01-12 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT05609968 Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung | Carcinoma, Non-Small-Cell Lung | active not recruiting | 614 |
| 2027-01-15 est. | P3 | Regeneron Pharmaceuticals REGN | NCT05608291 A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has | Melanoma | active not recruiting | 1564 |
| 2027-01-15 est. | P2/P3 | IDEAYA Biosciences IDYA | NCT05987332 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Metastatic Uveal Melanoma | active not recruiting | 420 |
| 2027-01-29 est. | P3 | Seagen, a wholly owned subsidiary of Pfizer | NCT05911295 Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Urothelial Carcinoma | active not recruiting | 412 |
| 2027-01-30 est. | P1/P2 | Psivac Ltd | NCT06549946 Ixovex-1 Single Agent and Combination Therapy | Solid Tumor; Head and Neck Cancer | recruiting | 18 |
| 2027-01-31 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04241185 Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-99 | Urinary Bladder Neoplasms | active not recruiting | 520 |
| 2027-02 est. | P3 | Gilead Sciences GILD | NCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Ad | Triple Negative Breast Cancer; PD-L1 Positive | active not recruiting | 443 |
| 2027-02 est. | P1/P2 | Krystal Biotech, Inc. KRYS | NCT06228326 A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Lung Cancer, Non-small Cell; Lung Cancer Metastatic; Solid Tumor, Adult; Advanced Cancer; Lung Cance | recruiting | 250 |
| 2027-02-12 est. | P2 | Merck Sharp & Dohme LLC MRK | NCT03407144 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | Hodgkin Lymphoma | active not recruiting | 340 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-11 est. | P2 | Precigen, Inc PGEN | NCT06157151 PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | Cervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy; Recurrent Cervical Carcinoma; Metast | recruiting | 24 |
| 2026-11 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06448312 A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | active not recruiting | 406 |
| 2026-10-30 est. | P3 | Pfizer PFE | NCT04657991 A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | Melanoma | active not recruiting | 257 |
| 2026-10-28 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT05239728 A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrec | Carcinoma, Renal Cell | active not recruiting | 1800 |
| 2026-10-27 est. | P2 | AstraZeneca AZN | NCT06008093 A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherap | Carcinoma, Non-Small-Cell Lung | active not recruiting | 103 |
| 2026-10-26 | P2 | GlaxoSmithKline | NCT05565378 A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer | Lung Cancer, Non-Small Cell | active not recruiting | 351 |
| 2026-10-15 | P2 | Hoffmann-La Roche | NCT05852691 A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced | Breast Cancer | completed | 83 |
| 2026-10-05 | P2 | Hoffmann-La Roche | NCT05805501 A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinom | Renal Cell Carcinoma | completed | 199 |
| 2026-10-01 est. | P2 | Taiho Oncology, Inc. | NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Ade | active not recruiting | 53 |
| 2026-10 est. | P1/P2 | Immunocore Ltd IMCR | NCT04262466 Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Select Advanced Solid Tumors | active not recruiting | 410 |
| 2026-09-30 est. | P2 | Mirati Therapeutics Inc. | NCT05609578 Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | Advanced NSCLC; Metastatic Lung Cancer | active not recruiting | 90 |
| 2026-09-22 | P1/P2 | Tango Therapeutics, Inc. TNGX | NCT05887492 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Non Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer; Lung Adenocarcinoma | active not recruiting | 126 |
| 2026-09-22 est. | P1/P2 | ImmVira Pharma Co. Ltd | NCT04370587 A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Me | Solid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLC | recruiting | 30 |
| 2026-09-17 | P2 | Arcus Biosciences, Inc. RCUS | NCT04736173 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer | Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Can | completed | 169 |
| 2026-09-09 | P1/P2 | BioInvent International AB | NCT06784648 Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | Melanoma Metastatic; Melanoma of Skin; Melanoma BRAF V600E/K Mutated; Melanoma Recurrent; Melanoma S | active not recruiting | 35 |
| 2026-08-31 | P2 | Klus Pharma Inc. | NCT05816252 A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) | Non-small Cell Lung Cancer | active not recruiting | 356 |
| 2026-08-30 | P2 | OncoC4, Inc. | NCT05446298 ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer | Ovarian Cancer; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian T | active not recruiting | 58 |
| 2026-08-25 | P3 | PDS Biotechnology Corp. PDSB | NCT06790966 Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Cancer; Metastatic Head and Neck Cancer; HPV Positive Oropharyngeal Squamous | terminated | 12 |
| 2026-08-17 | P3 | AstraZeneca AZN | NCT05984277 A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. | Metastatic Non-small Cell Lung Cancer | active not recruiting | 895 |
| 2026-08-10 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT04626479 Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | Carcinoma, Renal Cell | completed | 393 |
| 2026-07-23 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT04626518 Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | Carcinoma, Renal Cell | completed | 263 |
| 2026-07-13 | P1/P2 | GlaxoSmithKline | NCT06405230 Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positro | Lung Cancer, Non-Small Cell | terminated | 2 |
| 2026-07-01 est. | P1/P2 | Scancell Ltd SCNLD | NCT05329532 Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer | Triple Negative Breast Cancer; Renal Cell Cancer; High Grade Ovarian Serous Adenocarcinoma; Squamous | recruiting | 168 |
| 2026-07 est. | P1/P2 | CJ Bioscience, Inc. | NCT05877430 Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | NSCLC; HNSCC; Melanoma; Metastatic Cancer; Advanced Solid Tumor; Advanced Cancer | recruiting | 160 |
| 2026-06-30 | P3 | GlaxoSmithKline | NCT06472076 A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) Hig | Lung Cancer, Non-Small Cell | active not recruiting | 88 |
| 2026-06-23 | P1/P2 | Mirati Therapeutics Inc. | NCT03785249 Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease | active not recruiting | 731 |
| 2026-06-22 | P1/P2 | Anaveon AG | NCT06470763 A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) | Advanced Solid Tumor | completed | 63 |
| 2026-06-19 | P2 | Pfizer PFE | NCT05217446 A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorecta | Metastatic Colorectal Cancer | active not recruiting | 108 |
| 2026-06-17 | P1/P2 | Precision Biologics, Inc DTIL | NCT03476681 Study of NEO-201 in Solid Tumors Expansion Cohorts | Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Cancer; Uterine Cancer | active not recruiting | 121 |
| 2026-06-09 | P3 | AstraZeneca AZN | NCT05048797 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small C | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | 454 |
| 2026-06-08 | P2 | Merck Sharp & Dohme LLC MRK | NCT04123366 Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Re | Solid Tumors | completed | 333 |
| 2026-06 est. | P1/P2 | 1ST Biotherapeutics, Inc. | NCT05761223 A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | Advanced Solid Tumor | recruiting | 151 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.